466 related articles for article (PubMed ID: 16788983)
1. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue.
Brown LM; Helmke SM; Hunsucker SW; Netea-Maier RT; Chiang SA; Heinz DE; Shroyer KR; Duncan MW; Haugen BR
Mol Carcinog; 2006 Aug; 45(8):613-26. PubMed ID: 16788983
[TBL] [Abstract][Full Text] [Related]
2. [Proteomics study of papillary thyroid carcinoma].
Shi J; Lu ZH; Cui QC
Zhonghua Bing Li Xue Za Zhi; 2008 Jul; 37(7):465-70. PubMed ID: 19035118
[TBL] [Abstract][Full Text] [Related]
3. Proteomic identification of new biomarkers and application in thyroid cytology.
Torres-Cabala C; Bibbo M; Panizo-Santos A; Barazi H; Krutzsch H; Roberts DD; Merino MJ
Acta Cytol; 2006; 50(5):518-28. PubMed ID: 17017437
[TBL] [Abstract][Full Text] [Related]
4. Proteomic study of thyroid tumors reveals frequent up-regulation of the Ca2+ -binding protein S100A6 in papillary thyroid carcinoma.
Sofiadis A; Dinets A; Orre LM; Branca RM; Juhlin CC; Foukakis T; Wallin G; Höög A; Hulchiy M; Zedenius J; Larsson C; Lehtiö J
Thyroid; 2010 Oct; 20(10):1067-76. PubMed ID: 20629554
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of S100C in thyroid lesions.
Torres-Cabala C; Panizo-Santos A; Krutzsch HC; Barazi H; Namba M; Sakaguchi M; Roberts DD; Merino MJ
Int J Surg Pathol; 2004 Apr; 12(2):107-15. PubMed ID: 15173915
[TBL] [Abstract][Full Text] [Related]
6. Proteome analysis identified maspin as a special feature of papillary thyroid carcinoma.
Boltze C; Schneider-Stock R; Quednow C; Gerlach R; Mawrin C; Hinze R; Roessner A; Hoang-Vu C
Int J Oncol; 2003 Nov; 23(5):1323-8. PubMed ID: 14532972
[TBL] [Abstract][Full Text] [Related]
7. S100-A10, thioredoxin, and S100-A6 as biomarkers of papillary thyroid carcinoma with lymph node metastasis identified by MALDI imaging.
Nipp M; Elsner M; Balluff B; Meding S; Sarioglu H; Ueffing M; Rauser S; Unger K; Höfler H; Walch A; Zitzelsberger H
J Mol Med (Berl); 2012 Feb; 90(2):163-74. PubMed ID: 21938494
[TBL] [Abstract][Full Text] [Related]
8. PDLIM5 identified by label-free quantitative proteomics as a potential novel biomarker of papillary thyroid carcinoma.
Wei X; Zhang Y; Yu S; Li S; Jiang W; Zhu Y; Xu Y; Yang C; Tian G; Mi J; Bergquist J; Zhao M; Song F
Biochem Biophys Res Commun; 2018 May; 499(2):338-344. PubMed ID: 29574154
[TBL] [Abstract][Full Text] [Related]
9. Proteomics for the diagnosis of thyroid lesions: preliminary report.
Pagni F; Mainini V; Garancini M; Bono F; Vanzati A; Giardini V; Scardilli M; Goffredo P; Smith AJ; Galli M; De Sio G; Magni F
Cytopathology; 2015 Oct; 26(5):318-24. PubMed ID: 25040579
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
Abouhashem NS; Talaat SM
Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
[TBL] [Abstract][Full Text] [Related]
11. Discovery and validation of protein abundance differences between follicular thyroid neoplasms.
Netea-Maier RT; Hunsucker SW; Hoevenaars BM; Helmke SM; Slootweg PJ; Hermus AR; Haugen BR; Duncan MW
Cancer Res; 2008 Mar; 68(5):1572-80. PubMed ID: 18316623
[TBL] [Abstract][Full Text] [Related]
12. Expression profile of biomarkers altered in papillary and anaplastic thyroid carcinoma: Contribution of Tunisian patients.
Fourati A; El Amine O; Ben Ayoub W; Cherni I; Goucha A; El May MV; Gamoudi A; El May A
Bull Cancer; 2017 May; 104(5):433-441. PubMed ID: 28185633
[TBL] [Abstract][Full Text] [Related]
13. Proteomic profiling of follicular and papillary thyroid tumors.
Sofiadis A; Becker S; Hellman U; Hultin-Rosenberg L; Dinets A; Hulchiy M; Zedenius J; Wallin G; Foukakis T; Höög A; Auer G; Lehtiö J; Larsson C
Eur J Endocrinol; 2012 Apr; 166(4):657-67. PubMed ID: 22275472
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
[TBL] [Abstract][Full Text] [Related]
15. A multiplexed, targeted mass spectrometry assay of the S100 protein family uncovers the isoform-specific expression in thyroid tumours.
Martínez-Aguilar J; Clifton-Bligh R; Molloy MP
BMC Cancer; 2015 Mar; 15():199. PubMed ID: 25880590
[TBL] [Abstract][Full Text] [Related]
16. CDX2 expression in columnar cell variant of papillary thyroid carcinoma.
Enriquez ML; Baloch ZW; Montone KT; Zhang PJ; LiVolsi VA
Am J Clin Pathol; 2012 May; 137(5):722-6. PubMed ID: 22523209
[TBL] [Abstract][Full Text] [Related]
17. Imaging mass spectrometry in papillary thyroid carcinoma for the identification and validation of biomarker proteins.
Min KW; Bang JY; Kim KP; Kim WS; Lee SH; Shanta SR; Lee JH; Hong JH; Lim SD; Yoo YB; Na CH
J Korean Med Sci; 2014 Jul; 29(7):934-40. PubMed ID: 25045225
[TBL] [Abstract][Full Text] [Related]
18. Proteomic and postproteomic characterization of keratan sulfate-glycanated isoforms of thyroglobulin and transferrin uniquely elaborated by papillary thyroid carcinomas.
Magro G; Perissinotto D; Schiappacassi M; Goletz S; Otto A; Müller EC; Bisceglia M; Brown G; Ellis T; Grasso S; Colombatti A; Perris R
Am J Pathol; 2003 Jul; 163(1):183-96. PubMed ID: 12819023
[TBL] [Abstract][Full Text] [Related]
19. [Proteomics and its applications in the research of papillary thyroid carcinoma].
Shi J; Lu ZH; Cui QC
Zhonghua Bing Li Xue Za Zhi; 2007 Oct; 36(10):691-3. PubMed ID: 18194605
[No Abstract] [Full Text] [Related]
20. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy.
Siraj AK; Bavi P; Abubaker J; Jehan Z; Sultana M; Al-Dayel F; Al-Nuaim A; Alzahrani A; Ahmed M; Al-Sanea O; Uddin S; Al-Kuraya KS
J Pathol; 2007 Oct; 213(2):190-9. PubMed ID: 17703498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
